HALIFAX, NS / / January 9, 2025 / Today, MedMira Inc. (MedMira) (TSXV:MIR) announced that its received investigational ...
GlobalData on MSN21d
Health Canada approves MedMira’s rapid test for HIV and syphilisThe test enables healthcare professionals to identify HIV-1/2 and syphilis antibodies from a single finger prick sample.
Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...
The rising global incidence of syphilis underscores the risk of transmission through blood transfusions. Treponema pallidum, the pathogen responsible for syphilis, represents a major public health ...
MedMira receives Health Canada approval for its Multiplo(R) Rapid (TP/HIV) Test for Syphilis and HIV
The single Reveal® TP (Syphilis) approval will follow soon after this more complex approval. The Multiplo® TP/HIV rapid test allows healthcare professional to accurately detect both HIV-1/2 and ...
The approval of the ITA is an important step towards getting the Multiplo ® Complete Syphilis (TP/nTP) Antibody Test licensed and into the Canadian market. MedMira offers the only commercially ...
The Multiplo TP/HIV rapid test allows healthcare professional to accurately detect both HIV-1/2 and syphilis antibodies with one sample using a simple finger prick that delivers results immediately.
HALIFAX, NS / ACCESSWIRE / January 9, 2025 / Today, MedMira Inc. (MedMira) (TSXV:MIR) announced that its received investigational testing authorization (ITA) from Health Canada to begin clinical trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback